The Effects of Audio-Based Therapy on Anxiety in Psoriasis (NCT07390487) | Clinical Trial Compass
RecruitingNot Applicable
The Effects of Audio-Based Therapy on Anxiety in Psoriasis
United States120 participantsStarted 2026-02-01
Plain-language summary
Anxiety in psoriasis is associated with impaired quality of life, and the prevalence of anxiety symptoms in psoriatic populations is approximately 34% and anxiety disorders up to 16%. Many experts recommend routine screening, referral, and interventions for anxiety in psoriasis; however, many barriers inhibit access to mental health resources and proper management. To our knowledge, there is a lack of easily accessible interventions that manage anxiety. Audio-based therapy offers convenient and effective interventions that show reduced anxiety in published, randomized studies and is a promising management for psoriasis patients. This study will evaluate the effects of audio therapy in patients with psoriasis and measure changes in overall symptoms.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥18 years
* Self-reported dermatologist-diagnosed psoriasis
* GAD 2-Item Score ≥1 at screening
* Ability to consent and complete pre- and post-intervention surveys.
* Internet access and the ability to use a computer/smartphone with headphones for a single 23-30 minute session at home.
Exclusion Criteria:
* Severe hearing impairment precluding headphone listening
* Any condition requiring strict sound avoidance (such as seizure/epilepsy, major head trauma, severe sound-triggered migraine) that would make participation unsafe.
* Other diagnoses that in the investigator's judgment preclude safe participation or interfere with anxiety or psoriasis evaluation.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Anxiety: State Trait Inventory for Cognitive and Somatic Anxiety (STICSA)
Timeframe: From the pre-intervention survey to the post-intervention survey, approximately 30 minutes.
Trial details
NCT IDNCT07390487
SponsorUniversity of California, San Francisco
Sponsor typeOTHER
Study typeINTERVENTIONAL
Primary completion2027-12
Contact for this trial
Amélie Spangenberg, Psoriasis Clinical Research Fellow, MBBS